| Excerpt | Reference |
|---|
| "Mixed alveolar interstitial pneumonia is a much-feared complication in bone marrow transplant recipients because it carries a high mortality." | ( Fibbe, WE; Kroes, AC; van Dissel, JT; Zijlmans, JM, 1995) |
| "Interstitial pneumonia is characterized by alveolitis with resulting fibrosis of the interstitium." | ( Abe, K; Harada, S; Hayashi, S; Kaneda, Y; Matsumoto, N; Saito, I; Sakatani, M; Sakuma, J; Yamamoto, S; Yoshida, M, 1995) |
| "Acute interstitial pneumonitis is the main pulmonary side effect during methotrexate (MTX) treatment for rheumatoid arthritis." | ( Bernard, JP; Cottin, V; Massonnet, B; Souquet, PJ; Tébib, J, 1996) |
| "Pancytopenia and interstitial pneumonitis are one of the most serious and unpredictable adverse effects of low dose, pulse methotrexate (MTX) in treating rheumatoid arthritis (RA)." | ( Akizuki, M; Hama, N; Hirakata, M; Ikeda, Y; Kameda, H; Kuwana, M; Matsumura, M; Mimori, T; Nakamura, K; Nojima, T; Ogasawara, T; Ohosone, Y; Okano, Y; Yoshida, T, 1997) |
| "Interstitial lung disease is a rare manifestation of NPD." | ( Minai, OA; Stoller, JK; Sullivan, EJ, 2000) |
| "As interstitial pneumonitis is a potentially fatal but reversible complication, early respiratory symptoms even in patients on low-dose MTX treatment should be appropriately investigated." | ( Ameen, M; Barkert, JN; Taylor, DA; Wells, AU; Williams, IP, 2001) |
| "Since fatal interstitial pneumonia is frequently associated with amyopathic DM as in this case, administration of CyA should be actively considered as a therapeutic option when clinical symtoms are progressive and resistant to conventional treatments." | ( Hashimoto, T; Hoshi, K; Ikeda, S; Ishii, W; Kato, T; Matsuda, M; Shimojima, Y; Tanaka, Y, 2003) |
| "Interstitial lung disease is a common complication of many of the connective tissue diseases." | ( Highland, KB; Strange, C, 2004) |
| "Diffuse parenchymal lung disease is associated with a high risk of mortality despite early referral and listing for lung transplantation." | ( Arcasoy, SM; Bartels, MN; Kawut, SM; O'Shea, MK; Sonett, JR; Wilt, JS, 2005) |
| "Most of the interstitial lung diseases are rare, chronic, progressive and fatal disorders, especially in familial form." | ( Hong, SJ; Huh, J; Jang, JY; Kim, HB; Kim, JH; Lee, SY; Park, SJ, 2005) |
| "Gemcitabine- induced interstitial pneumonitis is very rare, but could become a serious complication in long-term gemcitabine treatment." | ( Fujita, S; Hirota, M; Inoue, Y; Nomura, M; Sakao, J; Souda, S, 2006) |
| "Interstitial lung disease is a serious complication of polymyositis/dermatomyositis and leads to death from chronic respiratory insufficiency in 30 to 66% of cases." | ( Dominique, S; Marie, I, 2006) |
| "Interstitial lung disease is the most important feature, as it determines survival and the therapeutic attitude." | ( Dayer, E; Jordan Greco, AS; Métrailler, JC, 2007) |
| "Acute interstitial pneumonitis is the main pulmonary side effect during MTX treatment." | ( Marquina Barcos, A; Monón Ballarín, S; Mozota Duarte, J; Ruiz-Ruiz, FJ; Sáenz Abad, D, 2008) |
| "Interstitial lung disease is an important cause of mortality and morbidity in patients with systemic sclerosis (SSc)." | ( Browne, P; Kearns, G; O'Connell, P; O'Neill, L; Peshin, R, 2009) |
| "Smoking-related interstitial lung diseases are characterized by the accumulation of macrophages and Langerhans cells, and fibrotic remodeling, which are linked to osteopontin (OPN) expression." | ( Ask, K; Bargagli, E; Kayser, G; Kirschbaum, A; Kolb, M; Müller-Quernheim, J; Prasse, A; Renkl, AC; Schulz, G; Stahl, M; Wang, L; Weiss, JM; Yalcintepe, J; Zissel, G, 2009) |
| "Thalidomide-induced interstitial pneumonitis is rare, and only 4 cases have been reported in the literature." | ( Hasejima, N; Matsushima, H; Oda, T; Sato, A; Takezawa, S; Yamamoto, M, 2009) |
| "Interstitial lung disease is a common manifestation of rheumatoid arthritis; however, little is known about factors that influence its prognosis." | ( Collard, HR; Elicker, BM; Kim, EJ; King, TE; Lee, JS; Maldonado, F; Ryu, JH; Van Uden, JH; Webb, WR, 2010) |
| "Interstitial pneumonia is the most serious adverse event for both agents." | ( Oya, M, 2010) |
| "Interstitial lung disease is a serious but uncommon side effect of this relatively safe drug." | ( Kalra, A; Kurmayagari, K; Palaniswamy, C; Sekhri, A; Selvaraj, DR, 2012) |
| "Interstitial lung disease is commonly associated with the autoimmune inflammatory myopathies dermatomyositis and polymyositis and accounts for significant morbidity and mortality in these conditions." | ( Christopher-Stine, L; Connors, GR; Danoff, SK; Oddis, CV, 2010) |
| "PTU-induced interstitial pneumonia is rare--only three cases have been reported--and PTU-induced nonspecific interstitial pneumonia (NSIP) has not been reported." | ( Chung, JH; Kim, SY; Koo, HK; Lee, CT; Lee, JH; Lee, JY; Lee, YJ; Park, SS; Yoon, HI, 2011) |
| "Bicalutamide-induced interstitial pneumonitis is quite rare." | ( Masago, T; Motoda, K; Nemoto, R; Watanabe, T, 2011) |
| "Interstitial lung disease is a rare but potentially fatal side effect of pemetrexed." | ( Benz, G; Brutsche, M; Früh, M; Hochstrasser, A; Joerger, M; Templeton, A, 2012) |
| "Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP." | ( Berkahn, L; Child, N; O'Carroll, M, 2012) |
| "Interstitial lung disease is a major adverse drug reaction associated with everolimus, and interstitial lung disease is the first condition suspected when a patient presents with pneumonitis during everolimus therapy." | ( Gemma, A; Kimura, G; Kondo, Y; Minegishi, Y; Miura, Y; Nagayama, M; Noro, R; Ogushi, S; Saito, Y; Suzuki, Y, 2013) |
| "Since interstitial pneumonitis is a serious adverse drug reaction during interferon therapy, interferon treatment requires caution in respiratory disease patients." | ( Abe, H; Hirose, K; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Nagashima, A; Seki, K; Togashi, T; Yoshida, T, 2012) |
| "Acute interstitial pneumonia is one of serious side effects of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment, while it often has significant clinical benefit in cancer patients." | ( Ishiguro, H; Ishiguro, Y; Miyamoto, H, 2013) |
| "Interstitial lung disease is still an adverse drug reaction of interest in this population, and these results, including ILD risk factors, give helpful information for treatment selection and monitoring." | ( Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N, 2014) |
| "Interstitial lung disease is the most common complication and cause of death among patients with scleroderma." | ( Azuma, A; Fujita, K; Hayashihara, K; Miura, Y; Nei, T; Rin, S; Saito, T; Sekine, A; Takoi, H; Tanaka, T; Tsunoda, Y; Yatagai, Y, 2014) |
| "Interstitial lung disease is one of the most serious pulmonary complications, and the early diagnosis is essential to initiate a prompt therapy." | ( Callejas Rubio, JL; González García, A; Ortego Centeno, N; Ríos Fernández, R, 2016) |
| "Giant cell interstitial pneumonia is a rare lung disease and is considered pathognomonic for hard metal lung disease, although some cases with no apparent hard metal (tungsten carbide cobalt) exposure have been reported." | ( Alvarez, F; Colby, TV; Elrefaei, M; Erasmus, DB; Keller, CA; Khoor, A; Mallea, JM; Murray, DL; Roden, AC; Roggli, VL, 2016) |
| "Interstitial lung disease is a rare but serious toxicity due to the high mortality risk." | ( Afqir, S; Brahmi, SA; Youssef, S; Ziani, FZ, 2016) |
| "As interstitial pneumonitis is a rare adverse event during anagrelide-therapy administration, physicians must be vigilant in identifying drug-induced interstitial pneumonitis in patients treated with anagrelide because early detection can decrease the severity and prevent mortality." | ( Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M, 2017) |
| "Giant cell interstitial pneumonia is the classic pathologic pattern, but cobalt related ILD may also present with pathologic findings of UIP, DIP, or HP." | ( Adams, TN; Batra, K; Butt, YM; Glazer, CS, 2017) |
| "However, interstitial lung disease is a rare but severe and fatal side effect of crizotinib that should lead to immediate discontinuation of the drug." | ( Liu, K; Pan, D; Ren, F; Wu, S; Zheng, D, 2018) |
| "Fibrosing interstitial lung disease is the poor prognostic non-infectious lung disease by unknown etiology." | ( Gatanaga, H; Kikuchi, Y; Oka, S; Shimoda, Y; Suzuki, T; Teruya, K; Watanabe, K, 2019) |
| "Interstitial lung disease is prevalent and morbid condition in RA (RA-ILD), affecting up to 60% of patients with RA, leading to premature death in 10% and accruing an average of US$170,000 in healthcare costs per patient over a 5-year period." | ( Chambers, DC; Danoff, SK; Dellaripa, PF; DiFranco, D; Goldberg, HJ; Haynes-Harp, S; Hurwitz, S; Kolb, M; Peters, EB; Rosas, IO; Solomon, JJ; Spino, C; Woodhead, F, 2019) |
| "Interstitial lung disease is the major determinant of morbidity and mortality." | ( Laube, I; Maurer, B; Rüegg, CA; Scholtze, D, 2019) |
| "Interstitial pneumonia is common and has high short-term mortality in patients with PM and DM despite glucocorticoid (GC) treatment." | ( Atsumi, T; Hayashi, T; Hirakata, M; Ito, S; Itoh, K; Katada, Y; Kawahata, K; Kawakami, A; Kishi, J; Miyasaka, N; Takada, K; Takasaki, Y; Watanabe, N; Yamashita, H, 2020) |
| "Interstitial lung disease is the targeted adverse drug reaction in the use-results survey mandated in the re-examination of those drugs." | ( Chandler, RE; Fujiyoshi, Y; Iwasa, E; Kimura, R; Kubota, Y; Norén, GN; Taavola, H; Wakao, R, 2020) |
| "Everolimus-induced interstitial pneumonia is often mild, but it can be severe in rare cases." | ( Hasegawa, T; Hirakawa, K; Kashiwagi, S; Kinoshita, H; Nakamoto, K; Ohira, M; Teraoka, H, 2020) |
| "Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course." | ( Baillet, C; Béhal, H; Hachulla, E; Huglo, D; Launay, D; Le Gouellec, N; Ledoult, E; Mékinian, A; Morelle, M; Remy-Jardin, M; Sobanski, V; Soussan, M, 2021) |
| "Trastuzumab‒induced interstitial pneumonia is rare, but we must be aware of the possibility that patients may develop severe pulmonary disorders or experience cardiotoxic effects." | ( Aizu, K; Fujieda, H; Furuta, M; Iwata, T; Kageyama, Y; Kobayashi, S; Sato, F; Toyoda, Y; Watanabe, S; Yamaguchi, R, 2021) |
| "Incidence of interstitial lung disease is higher in men, smokers, and patients with pulmonary fibrosis." | ( Adli, M; Aliyev, A; Besiroglu, M; Simsek, M; Turk, HM, 2021) |
| "TDM-1-associated interstitial lung disease is referred to as pneumonitis." | ( Araz, M; Artaç, M; Çelik, AF; Demirkıran, A; Karaağaç, M; Karakurt Eryılmaz, M; Uğraklı, M, 2022) |
| "Giant cell interstitial pneumonia is even rarer in lung transplant recipients." | ( Marshall, T; Mehta, AC; Mukhopadhyay, S; Ntiamoah, P; You, JY, 2022) |
| "Interstitial lung disease is the most common adverse event leading to discontinuation of alectinib." | ( Sato, J; Shimizu, T; Uchida, M; Wakabayashi, H, 2022) |
| "Drug-induced interstitial lung disease is usually a diagnosis of exclusion, difficult to identify particularly during the COVID-19 pandemic for patients with cancer." | ( Basaran, G; Cuhadaroglu, C; Gumusay, O; Isiklar, A; Kocagoz, AS; Sepin, B, 2023) |
| "Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%." | ( Adamali, HI; Chambers, DC; Chaudhuri, N; Cox, PG; Danoff, SK; Dellaripa, PF; Flaherty, KR; Forrest, IA; Gibbons, MA; Glaspole, I; Goldberg, HJ; Golden, J; Gooptu, B; Hurwitz, S; Kolb, M; Lasky, JA; Lynch, DA; Maurer, R; Perrella, MA; Raghu, G; Rosas, IO; Scholand, MB; Solomon, JJ; Spencer, LG; Spino, C; Troy, L; Vassallo, R; Woodhead, FA, 2023) |
| "Interstitial lung disease is an early complication of SSc and the main cause of death from SSc." | ( Wang, D; Wei, Y; Xu, L; Zhang, J, 2023) |
| "Key Points • Interstitial lung disease is a common manifestation of several connective tissue diseases and its progressive fibrosing phenotype contributes to high mortality rate and many unmet needs regarding the treatment remain." | ( Anić, B; Barešić, M; Karanović, B; Mirić, F; Novak, S; Perković, D; Radić, M, 2023) |
| Excerpt | Reference |
|---|
| "However, this induced severe interstitial pneumonitis, which was not cured by discontinuation of the drug, but disappeared completely with six episodes of methylprednisolone pulse therapy." | ( Fujimoto, T; Ishii, Y; Matsuda, S; Yamada, H, 1995) |
| "Fifty days after BMT, she suffered interstitial pneumonitis and a gastric ulcer, and was treated with a high dose of methylprednisolone and cimetidine." | ( Eizuru, Y; Minamishima, Y; Mizuno, S; Tamura, K, 1995) |
| "We found a higher incidence of interstitial pneumonitis in patients with primary biliary cirrhosis (14%) and describe its clinical manifestations, treatment, and possible etiology." | ( Kaplan, MM; McKusick, A; Provenzale, D; Sharma, A, 1994) |
| "We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine (BCNU) for a brain tumor." | ( Delaval, P; Desrues, B; Le Coz, A; Lena, H; Quinquenel, ML, 1994) |
| "Acute interstitial pneumonitis is the main pulmonary side effect during methotrexate (MTX) treatment for rheumatoid arthritis." | ( Bernard, JP; Cottin, V; Massonnet, B; Souquet, PJ; Tébib, J, 1996) |
| "We describe a case of interstitial pneumonitis associated with polymyositis who responded well to cyclosporine therapy." | ( Hagiwara, E; Igarashi, T; Ishigatsubo, Y; Okubo, T; Shirai, A; Soga, T, 1996) |
| "We conclude that the frequency of interstitial lung disease is high in Sjögren's syndrome and that an azathioprine-based treatment can favorably change the outcome in this population." | ( Barbas Filho, JV; Capelozzi, VL; de Carvalho, CR; Deheinzelin, D; Kairalla, RA; Saldiva, PH, 1996) |
| "Four months later, he developed severe interstitial pneumonitis, and his symptoms were not improved by high-dose steroid pulse and cyclophosphamide pulse treatment." | ( Chiba, S; Horigome, I; Hotta, O; Kitamura, H; Miyazawa, S; Sudou, K; Taguma, Y; Tokoi, T, 1996) |
| "Pancytopenia and interstitial pneumonitis are one of the most serious and unpredictable adverse effects of low dose, pulse methotrexate (MTX) in treating rheumatoid arthritis (RA)." | ( Akizuki, M; Hama, N; Hirakata, M; Ikeda, Y; Kameda, H; Kuwana, M; Matsumura, M; Mimori, T; Nakamura, K; Nojima, T; Ogasawara, T; Ohosone, Y; Okano, Y; Yoshida, T, 1997) |
| "We treated three cases of interstitial pneumonitis (IP) in 26 elderly (> or = 65 years old) patients with non-Hodgkin's lymphoma (NHL) who received the same chemotherapeutic protocol including granulocyte colony-stimulating factor (G-CSF) administration." | ( Abe, T; Hasegawa, Y; Kamoshita, M; Kobayashi, T; Kojima, H; Nagasawa, T; Ninomiya, H; Ohtani, K, 1997) |
| "Since interstitial pneumonitis may be fatal and irreversible, attention should be paid to this rare complication even in patients undergoing low-dose oral cyclophosphamide treatment." | ( Baba, K; Harigaya, H; Matsubara, K; Nigami, H, 1997) |
| "Many of these patients die from interstitial lung disease despite discontinuation of the drug and addition of corticosteroid treatment." | ( Ishioka, S, 1997) |
| "So we diagnosed the interstitial pneumonitis as CMV pneumonia and ganciclovir was administrated." | ( Etoh, T; Honda, A; Inaba, H; Ishida, I; Muro, H; Nagashima, Y; Nakajima, H; Nishimura, T; Ohta, S; Takamochi, K, 1997) |
| "We describe herein two cases of acute interstitial pneumonitis after administration of docetaxel to patients suffering from metastatic non-small cell lung cancer." | ( Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S, 1998) |
| "We present a case of acute interstitial pneumonitis in a patient who was treated with hydroxyurea for essential thrombocythemia." | ( Bello, JL; Bendaña, A; Gonzalez, S; Pérez-Encinas, M; Quintás-Cardama, A, 1999) |
| "We describe two cases of interstitial lung disease in patients with non-Hodgkin's lymphoma who were treated with combination chemotherapy including mitozantrone." | ( Johnson, S; Nicholson, AG; Rule, S; Stone, R; Tighe, M; Tomlinson, J, 1999) |
| "The signs and symptoms of drug-induced interstitial pneumonitis occur from within several hours up to months or years after the start of treatment, and sometimes even after the cessation of treatment, and consist of a dry cough, dyspnoea, fever and crackles upon auscultation." | ( Kaajan, JP; van der Drift, MA, 2002) |
| "Treatment of interstitial lung disease (ILD) in rheumatoid arthritis (RA) has been controversial." | ( Chang, HK; Park, W; Ryu, DS, 2002) |
| "We report here an unusual case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate treatment for metastatic prostate cancer." | ( Sakai, N; Shioi, K; Yoshida, M, 2003) |
| "A high incidence of interstitial lung disease (ILD) has been reported in patients with non-small cell lung cancer (NSCLC) treated with gefitinib in Japan." | ( Kodama, T; Kunitoh, H; Kusumoto, M; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Yamamoto, N; Yamamoto, S, 2004) |
| "The variable response of some interstitial lung diseases to steroid treatment may be the result of differences in the expression of GRalpha." | ( Cidlowski, JA; Mullol, J; Picado, C; Pujols, L; Ramírez, J; Roca-Ferrer, J; Torrego, A; Xaubet, A, 2004) |
| "Therefore, we should appropriately treat interstitial pneumonia in ADM even if it is NSIP." | ( Fujii, T; Hayashi, T; Kakugawa, T; Kohno, S; Mukae, H; Sakamoto, N; Yamaguchi, H; Yoshioka, S, 2004) |
| "RA associated interstitial lung disease (ILD) is often subtle in onset, slowly progressive and of unclear etiology and response to treatment." | ( Horton, MR, 2004) |
| "We report a case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment." | ( Nakamura, M; Sakai, N; Shioi, K; Yoshida, M, 2005) |
| "A lung biopsy was consistent with interstitial pneumonitis and following withdrawal of the drug and treatment with steroids her symptoms resolved." | ( Archibald, N; Black, F; Corris, PA; Dark, J; Lordan, J; Murphy, D; Yates, B, 2006) |
| "The authors report a case of interstitial lung disease (ILD) induced by gefitinib, which improved promptly following cessation of the administration of the agent." | ( Abe, S; Harada, K; Inomata, S; Kanai, A; Kitajima, H; Saikai, T; Takahashi, H; Taniguchi, H, 2006) |
| "He was also complicated with interstitial pneumonitis and was given a pulse therapy with methyl prednisolone followed by daily administration of 55 mg prednisolone (PSL)." | ( Hagiyama, H; Iwai, H; Kohsaka, H; Koike, R; Kubota, T; Miyasaka, N; Nagasaka, K; Nanki, T; Nishio, J; Nonomura, Y; Ogawa, J; Sugihara, T; Tsubata, R, 2002) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "Four patients with interstitial lung disease who were treated by amiodarone for ischemic heart diseases were evaluated by a conventional clinical workup." | ( Fireman, E; Priel, IE; Topilsky, I; Viskin, S, 2007) |
| "We report two cases of interstitial lung disease possibly related to TNF alpha antagonist therapy (etanercept) in patients with rheumatoid arthritis." | ( Dubost, JJ; Ledoux-Eberst, J; Poujol, D; Ristori, JM; Soubrier, M; Tournadre, A, 2008) |
| "The prognosis of interstitial lung disease associated with polymyositis is better than that of idiopathic pulmonary fibrosis, since most patients respond to treatment with corticosteroids and immunosuppressants." | ( Casanova, A; García, A; Girón, RM; Hoyos, N; Sánchez, S; Valenzuela, C, 2007) |
| "Acute interstitial pneumonitis is the main pulmonary side effect during MTX treatment." | ( Marquina Barcos, A; Monón Ballarín, S; Mozota Duarte, J; Ruiz-Ruiz, FJ; Sáenz Abad, D, 2008) |
| "We present a patient with COPD, in whom interstitial pneumonitis with radiologic features of organizing pneumonia developed after one year of amiodaron treatment due to supraventricular and ventricular arrhythmias." | ( Burakowska, B; Fijałkowska, A; Paczek, A; Szturmowicz, M; Torbicki, A; Wiatr, E, 2008) |
| "We report here two cases of interstitial lung disease occurring in association with the use of this combination chemotherapy." | ( Kato, S; Miyate, Y; Ogasawara, N; Ohori, H; Suzuki, M; Takahashi, M, 2009) |
| "A diagnosis of gefitinib-induced interstitial lung disease was made, and administration of high-dose prednisolone (1 g/day of intravenous methylprednisolone for three consecutive days, followed by oral prednisolone at 50 mg/day) was started." | ( Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y, 2010) |
| "Chemotherapy-induced interstitial lung disease (ILD) in colorectal cancer (CRC) patients is rarely reported, but its clinical features remain to be clarified." | ( Doi, T; Fuse, N; Joh, T; Minashi, K; Ohtsu, A; Shimura, T; Tahara, M; Yoshino, T, 2010) |
| "Currently, therapy for interstitial lung disease in patients with systemic sclerosis is unsatisfactory." | ( Bambery, P; Sharma, A; Sharma, S; Suryanaryana, BS; Wanchu, A, 2009) |
| "Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy." | ( Kochkareva, IuB; Kostina, IE; Stakhina, OV; Turkina, AG, 2010) |
| "In severe, progressive interstitial lung disease (ILD), specific diagnosis is often difficult, and treatment therefore empirical." | ( Corte, TJ; du Bois, RM; Ellis, R; Hansell, DM; Nicholson, AG; Renzoni, EA; Wells, AU, 2009) |
| "We investigated the incidence of acute interstitial lung disease (ILD) in SCLC patients who had been treated with amrubicin." | ( Goto, K; Kenmotsu, H; Kubota, K; Niho, S; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Yamaguchi, Y; Yoh, K, 2010) |
| "We present here a case of interstitial pneumonitis that occurred after S-1 treatment." | ( Kanematsu, S; Kasahara, N; Kwon, AH; Nakatake, R; Okukawa, H; Shoji, T; Tanaka, K; Ueyama, Y; Yamamoto, D; Yoshida, H, 2010) |
| "We describe herein a case of interstitial pneumonitis in a 49-year-old woman with relapsed ovarian carcinoma treated with PLD." | ( Arimoto, T; Hoya, M; Inaba, K; Kawana, K; Kozuma, S; Nakagawa, S; Taketani, Y, 2012) |
| "We describe interstitial pneumonitis induced by bicalutamide prescribed to treat prostate cancer." | ( Masago, T; Motoda, K; Nemoto, R; Watanabe, T, 2011) |
| "Irinotecan-induced interstitial lung disease (ILD) requires accurate diagnosis, followed by prompt and appropriate treatment." | ( Gemma, A; Kakihata, K; Kon, A; Nagashima, M; Suzuki, T; Yoshii, N, 2011) |
| "Small cell lung cancer with interstitial lung disease (ILD-SCLC) is difficult to treat because of the risk of fatal pneumonitis." | ( Higashiguchi, M; Hirashima, T; Kawase, I; Kobayashi, M; Matsuura, Y; Morishita, N; Okamoto, N; Sasada, S; Suzuki, H; Tamiya, M; Tsumori, T; Uehara, N, 2011) |
| "In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD), progressing despite maximal conventional immunosuppression, there is no effective medical rescue therapy." | ( Denton, CP; Hansell, DM; Keir, GJ; Maher, TM; Ong, VH; Renzoni, EA; Singh, S; Wells, AU, 2012) |
| "To elucidate the patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma, we reviewed seven cases of everolimus-induced interstitial lung disease." | ( Asano, K; Kaneko, G; Mikami, S; Mizuno, R; Nagata, H; Oya, M, 2012) |
| "In two cases with mild interstitial lung disease, the everolimus therapy was successfully continued." | ( Asano, K; Kaneko, G; Mikami, S; Mizuno, R; Nagata, H; Oya, M, 2012) |
| "Some patients who developed mild interstitial lung disease during everolimus treatment could continue to receive the treatment." | ( Asano, K; Kaneko, G; Mikami, S; Mizuno, R; Nagata, H; Oya, M, 2012) |
| "We diagnosed the patient with interstitial lung disease (grade 3) attributable to sunitinib administration." | ( Hirooka, N; Iwasaki, A; Matsuyama, S; Sekiguchi, Z; Takeshima, T; Takizawa, A; Tsuchiya, F, 2012) |
| "We experienced a case of interstitial lung disease (ILD) that occurred one year after the start of everolimus therapy for renal cell carcinoma." | ( Azuma, A; Fukuda, Y; Gemma, A; Kimura, G; Kondo, Y; Kunugi, S; Minegishi, Y; Miura, Y; Narita, K; Saito, Y; Suzuki, Y, 2013) |
| "Since interstitial pneumonitis is a serious adverse drug reaction during interferon therapy, interferon treatment requires caution in respiratory disease patients." | ( Abe, H; Hirose, K; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Nagashima, A; Seki, K; Togashi, T; Yoshida, T, 2012) |
| "In contrast, only one patient developed interstitial lung disease (Grade 1) in the chemotherapy arm." | ( Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N, 2013) |
| "Chemotherapy-associated interstitial lung disease (ILD) is often fatal, and the chemotherapeutic regimen generally cannot be resumed." | ( Goto, K; Hara, M; Ikeda, M; Kojima, M; Mitsunaga, S; Nakayama, Y; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H, 2013) |
| "Toxic interstitial pneumonitis was diagnosed and high-dose systemic corticosteroid methylprednisolone and inhalatory corticosteroid fluticasone therapy was started." | ( Brvar, M, 2014) |
| "Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects." | ( Azuma, A; Fujita, K; Hayashihara, K; Miura, Y; Nei, T; Rin, S; Saito, T; Sekine, A; Takoi, H; Tanaka, T; Tsunoda, Y; Yatagai, Y, 2014) |
| "We experienced a patient with interstitial pneumonitis that was induced by simeprevir with PEG-IFN and RBV therapy for chronic hepatitis C in the early stages of therapy (8 wk after initiating therapy)." | ( Okubo, A; Tamaki, K, 2015) |
| "The diagnosis of crizotinib-induced interstitial lung disease (ILD) was confirmed, and crizotinib was discontinued, followed by the initiation of corticosteroid therapy." | ( Chino, H; Kato, T; Kitamura, H; Ogura, T; Sekine, A, 2015) |
| "Pre-existing interstitial lung disease (pre-ILD) increases the risk of chemotherapy-related lung injury (CRLI)." | ( Abe, T; Akahori, D; Hasegawa, H; Koda, K; Matsui, T; Niwa, H; Ozawa, Y; Suda, T; Tanahashi, M; Yamada, K; Yokomura, K, 2016) |
| "Treatment of scleroderma-related interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide for 1 year both resulted in significant improvements in prespecified measures of lung function over the 2 year course of the study." | ( Arriola, E; Assassi, S; Clements, PJ; Connolly, MK; Dematte, J; Elashoff, RM; Fischer, A; Frech, T; Fritzler, MJ; Furst, DE; Golden, J; Goldin, J; Highland, K; Hinchcliff, ME; Hsu, VM; Hussain, S; Kafaja, S; Khanna, D; Kim, GHJ; Kleerup, EC; Martinez, F; Mayes, M; Meehan, R; Molitor, JA; Patel, B; Phillips, K; Read, CA; Riley, DJ; Roth, MD; Scholand, MB; Schraufnagel, DE; Silver, R; Simms, R; Steen, V; Strange, C; Swigris, J; Tashkin, DP; Theodore, A; Tseng, CH; Varga, J; Volkmann, ER; Volkov, S; Wigley, F; Wise, R, 2016) |
| "Although interstitial lung disease accounts for the majority of deaths of patients with systemic sclerosis, treatment options for this manifestation of the disease are limited." | ( Tashkin, DP; Volkmann, ER, 2016) |
| "Progressive interstitial lung disease (ILD) is a serious complication in SSc patients, and cyclophosphamide (CYC) is the only recommended therapy for this condition;(1)) however, its clinical effectiveness is not sufficient." | ( Kin, S; Nagamura, N, 2016) |
| "In particular interstitial lung disease (ILD) is a common pulmonary manifestation that may be related to the inflammatory process itself, infectious complications and to the treatments used." | ( Argento, G; D'Amelio, R; Giovagnoli, S; Laganà, B; Markovic, M; Picchianti Diamanti, A; Ricci, A, 2017) |
| "Here, we present the first case of interstitial lung disease occurring in association with TAS-102 treatment." | ( Akagi, Y; Ishibashi, N; Kamei, H; Tanigawa, M; Uchida, M; Yamaguchi, K, 2016) |
| "We present here a case of interstitial pneumonitis that occurred after lapatinib treatment." | ( Yamamoto, C; Yamamoto, D; Yamamoto, M, 2016) |
| "Both cases developed interstitial pneumonitis at 8 weeks after administration of anagrelide." | ( Ito, T; Kajiguchi, T; Kamoshita, S; Kimura, T; Yagi, M, 2017) |
| "However, treatment of other fibrosing interstitial lung diseases (ILD) remains challenging." | ( Behr, J; Kreuter, M; Wälscher, J, 2017) |
| "Chemotherapy-induced interstitial lung disease in colorectal cancer patients is rare but represents a life-threatening adverse reaction." | ( Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H, 2018) |
| "Patients with myositis-associated interstitial lung disease (MA-ILD) are often refractory to conventional treatment, and predicting their response to therapy is challenging." | ( Dua, A; Putman, MS; Sharma, N; Strek, ME; Vij, R, 2017) |
| "However, interstitial lung disease (ILD) is a very rare yet potentially fatal complication of RTX treatment." | ( Ahn, SH; Kim, SM; Sung, JJ, 2018) |
| "In response to treatment, interstitial pneumonia (IP) improved in three patients, stable in seven patients, and deteriorated in one patient." | ( Arawaka, S; Fujiki, Y; Hata, K; Konma, J; Kotani, T; Makino, S; Nagai, K; Shoda, T; Suzuka, T; Takeuchi, T; Yoshida, S, 2018) |
| "This report presents a case of interstitial pneumonitis accompanied by myelosuppression in a 74-year-old patient after receiving the fifth administration of mitomycin C through a ureteral catheter as a treatment for left kidney pyelocaliceal urothelial carcinoma." | ( Castro-Rebollo, P; Marco-Hernandez, J; Rodriguez-Reyes, M; Soy-Muner, D, 2019) |
| "To examine the deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept over the long-term." | ( Ikari, K; Mochizuki, T; Okazaki, K; Sato, M; Yano, K, 2019) |
| "Although SSc-associated interstitial lung disease (ILD) is one of the most important complications as a cause of death in SSc, prediction factors of treatment reactivity in SSc-ILD are still unclear." | ( Asano, Y; Ebata, S; Fukasawa, T; Hirabayashi, M; Kazoe, Y; Kitamori, T; Mawatari, K; Miura, S; Nakamura, K; Numajiri, H; Saigusa, R; Sato, S; Sumida, H; Yamashita, T; Yoshizaki, A, 2018) |
| "The possibility of interstitial pneumonitis should always be considered when a patient develops a fever and respiratory disorder during treatment containing TAS-102." | ( Hiramatsu, M; Imai, Y; Kobayashi, T; Kono, E; Sakane, J; Suzuki, Y; Tsunematsu, I, 2018) |
| "1) Drug-induced interstitial lung disease (DILD) is one of the serious adverse events associated with chemotherapy, and this retrospective study investigated the risk of DILD in Japanese patients with lung cancer." | ( Sakurada, T, 2018) |
| "Of those who developed interstitial lung disease, eight were treated with corticosteroids and three received cyclophosphamide pulse therapy." | ( Gemma, A; Hisakane, K; Kashiwada, T; Kubota, K; Minegishi, Y; Miyanaga, A; Noro, R; Saito, Y; Seike, M; Sugano, T; Takeuchi, S; Terasaki, Y, 2019) |
| "We present herein an instance of interstitial lung disease four weeks into alectinib treatment." | ( Dasanu, CA; Hwang, A; Iskandar, A, 2019) |
| "Acute exacerbation of pre-existing interstitial lung disease (ILD) associated with systemic anticancer therapy is recognized as a life-threatening adverse event of lung cancer treatment." | ( Atsumi, K; Gemma, A; Kashiwada, T; Kato, T; Kubota, K; Minegishi, Y; Saito, Y; Seike, M; Terasaki, Y, 2019) |
| "Childhood interstitial lung disease (ChILD) is a rare disease and sensitization is needed in the recognition, diagnosis and treatment approaches." | ( Vekaria-Hirani, V; Waris, A, 2018) |
| "Everolimus-related interstitial lung disease (ILD) (also: pneumonitis) poses a difficulty for physicians, as it is hard to discriminate ILD from other causes of respiratory symptoms and to decide on safe treatment continuation." | ( de Boer, M; de Jong, PC; Gerritsen, WR; Grutters, JC; Jonker, MA; Meek, B; Tol, J; van Erp, NP; van Herpen, CML; van Moorsel, C; Willemsen, AECAB, 2019) |
| "This report is a case of interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy." | ( Hongo, H; Kosaka, T; Oya, M; Yanai, Y, 2019) |
| "The symptomatic interstitial pneumonitis occurred in 12 patients who received DC/DC-T treatment with an incidence of 12." | ( Huang, L; Meng, L; Xu, Y; Zhang, W, 2020) |
| "Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), a primary cause of mortality in patients with RA, has limited treatment options." | ( Akimoto, T; Igarashi, T; Kajimoto, Y; Kanazawa, S; Kokuho, N; Kunugi, S; Maruyama, M; Miura, Y; Ohsawa, I; Shimizu, A; Terasaki, M; Terasaki, Y; Urushiyama, H, 2019) |
| "Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the most frequent cause of death for SSc but there is still no sufficient treatment available." | ( Asano, Y; Ebata, S; Fukasawa, T; Miura, S; Sato, S; Sumida, H; Takahashi, T; Yoshizaki, A, 2019) |
| "We diagnosed him with ceritinib-induced interstitial lung disease (ILD) and initiated methylprednisolone pulse therapy." | ( Hamaguchi, M; Hotta, T; Isobe, T; Okimoto, T; Tsubata, Y, 2020) |
| "The reversibility of interstitial lung disease (ILD) in SSc is difficult to assess by current diagnostic modalities and there is clinical need for imaging techniques that allow for treatment stratification and monitoring." | ( Hoekstra, OS; Meijboom, LJ; Nossent, EJ; Peelen, DM; Van der Laken, CJ; Voskuyl, AE; Zwezerijnen, BGJC, 2020) |
| "Fibrotic interstitial lung disease (f-ILD) has a guarded prognosis, and the goal of therapy in advanced-stage disease should be symptom-based." | ( Goh, N; Guo, H; Mann, J; Smallwood, N, 2020) |
| "Although rare, interstitial lung disease has been reported as among the adverse sequelae of pazopanib therapy." | ( Harada, Y; Kakimoto, S; Shimizu, T, 2020) |
| "Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening complication in patients with common variable immunodeficiency (CVID), but the optimal treatment is unknown." | ( Barbeau, J; Baruah, D; Bausch-Jurken, M; Busalacchi, A; Chen, S; Cool, CD; Feng, M; Hammelev, E; Hintermeyer, MK; Rao, N; Routes, JM; Rymaszewski, A; Simpson, PM; Sosa-Lozano, LA; Verbsky, JW; Woodliff, J, 2021) |
| "We investigated the risk of interstitial lung disease (ILD) and acute and chronic respiratory failure in persons with RA treated with MTX and other medications." | ( Cordtz, RL; Dreyer, L; Ibfelt, EH; Jacobsen, RK; Jakobsen, AS; Kopp, TI; Seersholm, N; Shaker, SB, 2021) |
| "Symptomatic interstitial lung disease (ILD) is rare in systemic lupus erythematosus (SLE), and there is no established treatment for it." | ( Fujio, K; Hanata, N; Shoda, H, 2021) |
| "Nintedanib reduced the progression of interstitial lung disease both in patients with SSc-ILD who were and were not using mycophenolate at baseline, with no heterogeneity in its treatment effect detected between the subgroups." | ( Allanore, Y; Assassi, S; Azuma, A; Bourdin, A; Clerisme-Beaty, E; Denton, CP; Distler, JHW; Distler, O; Gahlemann, M; Girard, M; Highland, KB; Hoffmann-Vold, AM; Khanna, D; Kuwana, M; Maher, TM; Mayes, MD; Raghu, G; Stowasser, S; Vonk, MC; Zoz, D, 2021) |
| "To compare risks of interstitial lung disease (ILD) between patients treated with dronedarone versus other antiarrhythmics." | ( Bohn, RL; Desai, V; Goehring, E; Jones, JK; Juhaeri, J; Sicignano, N; Tamayo, SG; Tave, A; Weiss, SR; Wu, C, 2021) |
| "Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment." | ( Lamb, YN, 2021) |
| "Treatment options for fibrotic interstitial lung diseases (ILDs) that involve progressive lung function decline have historically been limited." | ( Lamb, YN, 2021) |
| "Dyspnoea is common in patients with interstitial lung disease (ILD) and often refractory to conventional treatment." | ( Ariyoshi, K; Iwase, S; Matsuda, Y; Morita, T; Oyamada, S; Yamaguchi, T, 2021) |
| "On the 45th day of erlotinib treatment, interstitial lung disease occurred and erlotinib was discontinued." | ( Adli, M; Aliyev, A; Besiroglu, M; Simsek, M; Turk, HM, 2021) |
| "Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce." | ( Bonta, PI; Heunks, LMA; Jonkers, RE; Nossent, EJ; van den Berk, IAH; van Gemert, JP; Vlaar, AP, 2021) |
| "To investigate interstitial lung disease (ILD) in men with prostate cancer receiving hormone therapy." | ( Chen, C; Li, J; Shen, P; Wu, B; Wu, F; Xu, T; Yin, X; Yu, L, 2023) |
| "Among the lung toxicity signs, interstitial lung disease had the highest ROR, suggesting a strong causal relationship with alectinib treatment." | ( Sato, J; Shimizu, T; Uchida, M; Wakabayashi, H, 2022) |
| "Rapidly progressive (RP) interstitial lung disease (ILD) is a life-threatening complication of juvenile dermatomyositis (JDM); however, it is generally refractory to treatment; to the best of our knowledge, no evidence-based treatment has been established for RP-ILD yet." | ( Gima, M; Ide, K; Ito, S; Kamei, K; Koinuma, G; Nishi, K; Ogura, M; Tamai, N, 2022) |
| "Drug-induced interstitial lung disease (DI-ILD) is a serious adverse event during chemotherapy." | ( Akashi, T; Fujimori, N; Matsumoto, K; Miyagahara, T; Niina, Y; Ogawa, Y; Omori, K; Oono, T; Shimokawa, Y; Suehiro, Y; Tachibana, Y; Takamatsu, Y; Takaoka, T; Teramatsu, K; Ueda, K, 2023) |
| "Drug-induced interstitial lung disease (DI-ILD) is a serious adverse event during chemotherapy." | ( Akashi, T; Fujimori, N; Matsumoto, K; Miyagahara, T; Niina, Y; Ogawa, Y; Omori, K; Oono, T; Shimokawa, Y; Suehiro, Y; Tachibana, Y; Takamatsu, Y; Takaoka, T; Teramatsu, K; Ueda, K, 2023) |
| "Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies." | ( Adams, H; Grutters, JC; Keijsers, RG; Oyen, WJG; van de Garde, EMW; Vugts, DJ, 2023) |
| "Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC)." | ( Asama, H; Hashimoto, M; Hikichi, T; Imamura, H; Irie, H; Kato, T; Konno, N; Nakamura, J; Noguchi, Y; Ohira, H; Okubo, Y; Sato, Y; Shibukawa, G; Sugimoto, M; Suzuki, R; Takagi, T; Watanabe, K; Yanagita, T, 2023) |
| "Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy." | ( Agier, MS; Bejan-Angoulvant, T; Bermudez, J; Bonniaud, P; Borie, R; Brillet, PY; Cadranel, J; Caille, A; Cottin, V; Court-Fortune, I; Crestani, B; Debray, MP; Gomez, E; Gondouin, A; Hirschi-Santelmo, S; Israel-Biet, D; Jouneau, S; Juvin, K; Kerjouan, M; Leger, J; Mankikian, J; Marchand-Adam, S; Marquette, CH; Naccache, JM; Nunes, H; Plantier, L; Prevot, G; Quetant, S; Reynaud-Gaubert, M; Traclet, J; Uzunhan, Y; Valentin, V; Wémeau-Stervinou, L, 2023) |
| "Severe, life-threatening, or fatal interstitial lung disease/pneumonia has been reported in patients treated with crizotinib." | ( Fu, H; Gao, Z; He, Q; Jiang, F; Luo, P; Pan, Z; Xu, Z; Yan, H; Yang, B; Yang, X; Zhang, Y, 2023) |
| "The diagnosis of interstitial lung disease makes the treatment more difficult and worsens long-term prognosis and overall survival." | ( Anić, B; Barešić, M; Karanović, B; Mirić, F; Novak, S; Perković, D; Radić, M, 2023) |
| "Nintedanib is now widely used to treat interstitial lung disease (ILD)." | ( Hoshino, T; Matama, G; Murotani, K; Ohno, S; Okamoto, M; Takaki, R; Tominaga, M; Tsuneyoshi, S; Umemoto, S; Yano, R; Zaizen, Y, 2023) |